Saqib Islam was appointed chief executive officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as chief financial officer and chief business officer. Prior to joining SpringWorks Therapeutics, Saqib was chief business officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to joining Moderna, Saqib served as executive vice president, chief strategy and portfolio officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities.
Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.
Stephen Squinto, Ph.D.
Acting Head of Research and Development
Stephen Squinto, Ph.D., joined SpringWorks Therapeutics at launch in 2017 and is acting head of research and development. Steve is a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was a co-founder of Alexion Pharmaceuticals and recently served as its executive vice president and chief global operations officer. Prior to 2013, he was Alexion’s global head of research and development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Steve received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.
Jens Renstrup, M.D., MBA
Chief Medical Officer
Dr. Jens Renstrup is responsible for developing and driving execution of the clinical development programs and oversees medical affairs. Prior to joining SpringWorks Therapeutics, Jens was senior vice president and head of global medical affairs at Alexion Pharmaceuticals, where he helped to shape the company’s early- to late-stage development pipeline and was instrumental in building out a leading medical affairs function. Prior to Alexion, Jens served as vice president and head of global medical affairs at Glaxo Smith Kline Vaccines, where he developed the company’s medical strategy, which included evidence and engagement programs, and helped shape the development pipeline to support rapid drug applications in Europe, the United States and emerging markets. Jens also previously held progressive leadership positions at Merck & Co and started his career at IPSEN Scandinavia A/S.
Jens received a M.D. and specialist medical degree in anesthesiology and intensive care medicine from the University of Copenhagen, and an MBA from the Copenhagen Business School.
Badreddin Edris, Ph.D.
Chief Business Officer
Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was chief business officer) and Edgewise Therapeutics (where he was chief operating officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.
Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.
L. Mary Smith, Ph.D.
Senior Vice President, Clinical Research and Development
Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics Mary was the executive vice president of gene therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was vice president of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology.
Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.
Michael Greco, J.D.
General Counsel and Secretary
Michael Greco is responsible for the company’s legal and compliance functions. Prior to joining SpringWorks Therapeutics, Mike was senior vice president of law and corporate secretary for Alexion Pharmaceuticals. He joined Alexion shortly prior to the launch of Alexion’s first and lead product and during his tenure assumed positions of increasing responsibility in the company’s legal department. In his most recent role, he was responsible for overseeing corporate governance initiatives, public reporting and securities compliance and corporate transactions. He was also responsible for managing the legal department’s corporate, R&D, business development, and employment law legal teams. Prior to Alexion, Mike was a corporate attorney at Wiggin and Dana LLP and Bingham McCutchen LLP (now Morgan Lewis). Before law school, Mike served in the U.S. Army Corps of Engineers.
Mike received a J.D. from Suffolk University Law School and a Bachelor of Science degree from the United States Military Academy, West Point.
Head of Program and Alliance Management
Lisa Sinclair is responsible for portfolio management for the lead development programs and for alliance development with the company’s biopharmaceutical partners, including the collaboration with Pfizer. Lisa brings significant experience in driving the delivery of medicines from IND through approval in top tier global biopharmaceutical companies and has a proven track record of accelerating medicines to key decision points in rare diseases. Prior to joining SpringWorks Therapeutics, she served as vice president of R&D strategy, portfolio and project management at Alexion Pharmaceuticals where she led the development and execution of the five-year R&D strategic plan across multiple disease franchises and built portfolio and project management capabilities that supported pipeline speed, growth, and value. Prior to Alexion, Lisa was vice president of R&D portfolio and performance at AstraZeneca where she was accountable for transforming global portfolio management across R&D and implemented R&D therapeutic area planning, portfolio prioritization, resource management, and performance metrics and analytics. Prior to AstraZeneca, she held various roles of increasing responsibility at Pfizer.
Lisa received a bachelor’s degree in business from the University of Vermont.
Head of Communications and Investor Relations
Kim Diamond is responsible for internal and external communications and investor relations at SpringWorks Therapeutics. Prior to joining SpringWorks Therapeutics, Kim was executive director of corporate communications at Alexion Pharmaceuticals, where she was responsible for global external communications. Including strategic plans for corporate communications, company reputation and branding, global product launches, and digital communications. Prior to Alexion, Kim was director of corporate communications at OSI Pharmaceuticals, and she also held roles of increasing responsibility in the healthcare practice of Edelman earlier in her career.
Kim received a bachelor’s degree from Middlebury College.